靶向CD19的嵌合抗原受体T细胞治疗高级别B细胞淋巴瘤非特指型的疗效分析
该研究基于国际血液与骨髓移植研究中心(CIBMTR)注册库,纳入111例接受CD19 CAR-T治疗的高级别B细胞淋巴瘤非特指型(HGBCL-NOS)患者。细胞因子释放综合征发生率为74%(3级及以上7.7%),免疫效应细胞相关神经毒性综合征发生率为45.2%(3级及以上22.6%);2年总生存率和无进展生存率分别为41.6%和28.7%,2年非复发死亡率为3.1%,复发/进展率为68.1%。作者认为HGBCL-NOS患者即使接受CAR-T治疗仍属难治人群,仅三分之一患者获得持久缓解。
要点
- HGBCL-NOS患者CAR-T后细胞因子释放综合征发生率74%,3级及以上7.7%。
- 免疫效应细胞相关神经毒性综合征发生率45.2%,3级及以上22.6%。
- 2年总生存率41.6%,无进展生存率28.7%,复发/进展率68.1%。
核心结论
- HGBCL-NOS患者即使接受CAR-T治疗仍属特别难治的人群,仅约三分之一患者获得持久缓解。
- 与已发表的LBCL报告相比,HGBCL-NOS患者的总缓解率、总生存率和无进展生存率均较低。
研究设计与样本
- 基于国际血液与骨髓移植研究中心(CIBMTR)注册库的回顾性分析,纳入111例接受CD19 CAR-T治疗的高级别B细胞淋巴瘤非特指型(HGBCL-NOS)患者。
主要发现
- 细胞因子释放综合征发生率为74%,其中3级及以上为7.7%,中位发生时间为4天(范围1-17天)。
- 免疫效应细胞相关神经毒性综合征发生率为45.2%,其中3级及以上为22.6%,中位发生时间为7天(范围1-17天)。
- CAR-T输注后2年总生存率为41.6%,无进展生存率为28.7%。
- 2年非复发死亡率为3.1%(95%CI:0.6-7.6),复发/进展率为68.1%(95%CI:57.9-77.6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a pivotal part of the treatment algorithm for large B-cell lymphoma (LBCL) in the second- and third-line settings based on numerous clinical trials. However, these studies included very few patients with a diagnosis of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) and it is unclear if outcomes are similar to those observed with more common LBCL histologies. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we identified 111 HGBCL-NOS patients who received CAR-T therapy. The cytokine release syndrome (CRS) rate was 74% (7.7% grade 3+), median onset was 4 days (1-17) and immune effector cell-associated neurotoxicity syndrome rate was 45.2% (22.6% grade 3+), median onset was 7 days (1-17). At 2 years post-CAR-T infusion, the probability of overall survival and progression-free survival were 41.6% and 28.7% respectively. The 2-year non-relapse mortality and relapse/progression were 3.1% (95% confidence interval [CI]: 0.6-7.6) and 68.1% (95% CI: 57.9-77.6) respectively. Our analysis illustrates that patients with HGBCL-NOS represent a particularly difficult group to treat, even with CAR-T therapy. We observed that one third of patients achieved a durable response; however, the overall results were less favourable, with lower overall response rate, overall survival and progression-free survival as compared to published reports on LBCL.
引用
- Hossain NM, Ahn KW, Patel J, et al. Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS. Br J Haematol. 2025. PMID: 40693472. doi:10.1111/bjh.70020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。